Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients

Autores
Camprubí, Daniel; Almuedo Riera, Alex; Martí Soler, Helena; Soriano, Alex; Hurtado, Juan Carlos; Subirà, Carme; Grau Pujol, Berta; Krolewiecki, Alejandro Javier; Muñoz, José
Año de publicación
2020
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Ivermectin has recently shown efficacy against SARS-CoV-2 in-vitro. We retrospectively reviewed severe COVID-19 patients receiving standard doses of ivermectin and we compared clinical and microbiological outcomes with a similar group of patients not receiving ivermectin. No differences were found between groups. We recommend the evaluation of high-doses of ivermectin in randomized trials against SARS-CoV-2.
Fil: Camprubí, Daniel. Universidad de Barcelona; España
Fil: Almuedo Riera, Alex. Universidad de Barcelona; España
Fil: Martí Soler, Helena. Universidad de Barcelona; España
Fil: Soriano, Alex. Universidad de Barcelona; España
Fil: Hurtado, Juan Carlos. Universidad de Barcelona; España
Fil: Subirà, Carme. Universidad de Barcelona; España
Fil: Grau Pujol, Berta. Universidad de Barcelona; España
Fil: Krolewiecki, Alejandro Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Salta; Argentina. Universidad Nacional de Salta. Sede Regional Orán. Instituto de Investigación de Enfermedades Tropicales; Argentina
Fil: Muñoz, José. Universidad de Barcelona; España
Materia
COVID-19
SARS-COV-2
IVERMECTIN
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/160651
Acceder
id CONICETDig_abaf9d9f14205b3b2dfe9ec96e045132
oai_identifier_str oai:ri.conicet.gov.ar:11336/160651
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Lack of efficacy of standard doses of ivermectin in severe COVID-19 patientsCamprubí, DanielAlmuedo Riera, AlexMartí Soler, HelenaSoriano, AlexHurtado, Juan CarlosSubirà, CarmeGrau Pujol, BertaKrolewiecki, Alejandro JavierMuñoz, JoséCOVID-19SARS-COV-2IVERMECTINhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Ivermectin has recently shown efficacy against SARS-CoV-2 in-vitro. We retrospectively reviewed severe COVID-19 patients receiving standard doses of ivermectin and we compared clinical and microbiological outcomes with a similar group of patients not receiving ivermectin. No differences were found between groups. We recommend the evaluation of high-doses of ivermectin in randomized trials against SARS-CoV-2.Fil: Camprubí, Daniel. Universidad de Barcelona; EspañaFil: Almuedo Riera, Alex. Universidad de Barcelona; EspañaFil: Martí Soler, Helena. Universidad de Barcelona; EspañaFil: Soriano, Alex. Universidad de Barcelona; EspañaFil: Hurtado, Juan Carlos. Universidad de Barcelona; EspañaFil: Subirà, Carme. Universidad de Barcelona; EspañaFil: Grau Pujol, Berta. Universidad de Barcelona; EspañaFil: Krolewiecki, Alejandro Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Salta; Argentina. Universidad Nacional de Salta. Sede Regional Orán. Instituto de Investigación de Enfermedades Tropicales; ArgentinaFil: Muñoz, José. Universidad de Barcelona; EspañaPublic Library of Science2020-11info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/160651Camprubí, Daniel; Almuedo Riera, Alex; Martí Soler, Helena; Soriano, Alex; Hurtado, Juan Carlos; et al.; Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients; Public Library of Science; Plos One; 15; 11; 11-2020; 1-61932-6203CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0242184info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pone.0242184info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:06:47Zoai:ri.conicet.gov.ar:11336/160651instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:06:47.597CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients
title Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients
spellingShingle Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients
Camprubí, Daniel
COVID-19
SARS-COV-2
IVERMECTIN
title_short Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients
title_full Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients
title_fullStr Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients
title_full_unstemmed Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients
title_sort Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients
dc.creator.none.fl_str_mv Camprubí, Daniel
Almuedo Riera, Alex
Martí Soler, Helena
Soriano, Alex
Hurtado, Juan Carlos
Subirà, Carme
Grau Pujol, Berta
Krolewiecki, Alejandro Javier
Muñoz, José
author Camprubí, Daniel
author_facet Camprubí, Daniel
Almuedo Riera, Alex
Martí Soler, Helena
Soriano, Alex
Hurtado, Juan Carlos
Subirà, Carme
Grau Pujol, Berta
Krolewiecki, Alejandro Javier
Muñoz, José
author_role author
author2 Almuedo Riera, Alex
Martí Soler, Helena
Soriano, Alex
Hurtado, Juan Carlos
Subirà, Carme
Grau Pujol, Berta
Krolewiecki, Alejandro Javier
Muñoz, José
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv COVID-19
SARS-COV-2
IVERMECTIN
topic COVID-19
SARS-COV-2
IVERMECTIN
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Ivermectin has recently shown efficacy against SARS-CoV-2 in-vitro. We retrospectively reviewed severe COVID-19 patients receiving standard doses of ivermectin and we compared clinical and microbiological outcomes with a similar group of patients not receiving ivermectin. No differences were found between groups. We recommend the evaluation of high-doses of ivermectin in randomized trials against SARS-CoV-2.
Fil: Camprubí, Daniel. Universidad de Barcelona; España
Fil: Almuedo Riera, Alex. Universidad de Barcelona; España
Fil: Martí Soler, Helena. Universidad de Barcelona; España
Fil: Soriano, Alex. Universidad de Barcelona; España
Fil: Hurtado, Juan Carlos. Universidad de Barcelona; España
Fil: Subirà, Carme. Universidad de Barcelona; España
Fil: Grau Pujol, Berta. Universidad de Barcelona; España
Fil: Krolewiecki, Alejandro Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Salta; Argentina. Universidad Nacional de Salta. Sede Regional Orán. Instituto de Investigación de Enfermedades Tropicales; Argentina
Fil: Muñoz, José. Universidad de Barcelona; España
description Ivermectin has recently shown efficacy against SARS-CoV-2 in-vitro. We retrospectively reviewed severe COVID-19 patients receiving standard doses of ivermectin and we compared clinical and microbiological outcomes with a similar group of patients not receiving ivermectin. No differences were found between groups. We recommend the evaluation of high-doses of ivermectin in randomized trials against SARS-CoV-2.
publishDate 2020
dc.date.none.fl_str_mv 2020-11
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/160651
Camprubí, Daniel; Almuedo Riera, Alex; Martí Soler, Helena; Soriano, Alex; Hurtado, Juan Carlos; et al.; Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients; Public Library of Science; Plos One; 15; 11; 11-2020; 1-6
1932-6203
CONICET Digital
CONICET
url http://hdl.handle.net/11336/160651
identifier_str_mv Camprubí, Daniel; Almuedo Riera, Alex; Martí Soler, Helena; Soriano, Alex; Hurtado, Juan Carlos; et al.; Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients; Public Library of Science; Plos One; 15; 11; 11-2020; 1-6
1932-6203
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0242184
info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pone.0242184
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Public Library of Science
publisher.none.fl_str_mv Public Library of Science
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846781372883009536
score 13.129756

Publicaciones similares